Abstract
Early this year the DHSS directed manufacturers to stop recommending spironolactone for the treatment of hypertension and idiopathic oedema. Spiroprop (spironolactone + propranolol, Searle) intended for treating hypertension was therefore withdrawn. This decision was taken because the Licensing Authority had issued new toxicity data on canrenoate. Two separate unpublished studies from a Japanese pharmaceutical company suggested that high doses of the drug caused monomyelocytic leukaemia in rats.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
